If You Invested $1,000 in Catalyst Pharmaceuticals Stock One Year Ago, Here’s How Much You'd Have Now

A man looks at a stock market chart in Irvine, Calif., on April 9, 2021. John Fredricks/The Epoch Times

Investors who have owned stocks in the last year have generally experienced some big gains. In fact, the SPDR S&P 500 ETF Trust total return over the last 12 months is 29.5 percent. But there is no question some big-name stocks performed better than others along the way.

Catalyst’s Bumpy Ride

One company that has been a great investment in the last year has been the biopharmaceutical company Catalyst Pharmaceuticals Inc.

Catalyst Pharmaceuticals develops treatments for rare diseases, such as autoimmune disorder Lambert-Eaton Myasthenic Syndrome (LEMS). The big news for Catalyst in recent years came in 2018 when the company’s Firdapse became the first LEMS treatment ever approved in the U.S. Firdapse was subsequently approved in Japan in 2019.